CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

NCT06548412 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Biliary Tract Cancer

Interventions

DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Durvalumab
DRUG: CTX-009

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]